Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, 1756, 10.1200/JCO.1996.14.6.1756 Green, 2015, Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure, Oncologist, 20, 516, 10.1634/theoncologist.2014-0432 Kamradt, 2000, Etoposide in prostate cancer, Expert Opin Pharmacother, 1, 271, 10.1517/14656566.1.2.271 Conteduca, 2019, et al.: clinical features of neuroendocrine prostate cancer, Eur J Cancer, 121, 7, 10.1016/j.ejca.2019.08.011 Pommier, 2010, DNA topoisomerases and their poisoning by anticancer and antibacterial drugs, Chem Biol, 17, 421, 10.1016/j.chembiol.2010.04.012 Oser, 2019, et al.: cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival, Cancer Discov, 9, 230, 10.1158/2159-8290.CD-18-0389 Uxa, 2019, DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation, Nucleic Acids Res, 47, 9087, 10.1093/nar/gkz635 Schaefer-Klein, 2015, Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression, PLoS ONE, 10, 10.1371/journal.pone.0142327 Cheville, 2008, et al.: gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy, J Clin Oncol, 26, 3930, 10.1200/JCO.2007.15.6752 Hughes, 2006, Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma, J Clin Pathol, 59, 721, 10.1136/jcp.2005.029975 Willman, 2000, Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate, Prostate, 42, 280, 10.1002/(SICI)1097-0045(20000301)42:4<280::AID-PROS5>3.0.CO;2-P de Resende, 2013, Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer, J Transl Med, 11, 36, 10.1186/1479-5876-11-36 Haffner, 2010, Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements, Nat Genet, 42, 668, 10.1038/ng.613 Atwal, 2019, Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations, Mol Pharmacol, 96, 475, 10.1124/mol.119.117259 Mantoni, 2006, Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner, Oncogene, 25, 3139, 10.1038/sj.onc.1209347 Ferrari, 2017, et al.: adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer, Cell Commun Signal, 15, 51, 10.1186/s12964-017-0206-x Capaia, 2018, A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer, Int J Mol Sci, 19 Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 Gao, 2013, et al.: integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 10.1126/scisignal.2004088 Abida, 2019, Genomic correlates of clinical outcome in advanced prostate cancer, Proc Natl Acad Sci U S A, 10.1073/pnas.1902651116 Beltran, 2016, et al.: divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat Med, 22, 298, 10.1038/nm.4045 Hoadley, 2018, et al.: cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer, Cell, 173, 291, 10.1016/j.cell.2018.03.022 Berruti, 2005, Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up, Urol Oncol, 23, 1, 10.1016/j.urolonc.2004.06.003 Hussain, 1994, Oral etoposide in the treatment of hormone-refractory prostate cancer, Cancer, 74, 100, 10.1002/1097-0142(19940701)74:1<100::AID-CNCR2820740118>3.0.CO;2-K Joly, 2015, Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study, BJU Int, 115, 65, 10.1111/bju.12552 Papandreou, 2002, Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate, J Clin Oncol, 20, 3072, 10.1200/JCO.2002.12.065 Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Cancer Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309 Aggarwal, 2018, Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: a Multi-institutional Prospective Study, J Clin Oncol, 36, 2492, 10.1200/JCO.2017.77.6880 Hamid, 2019, Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer, Eur Urol, 76, 89, 10.1016/j.eururo.2018.11.045 Akamatsu, 2018, Clinical and molecular features of treatment-related neuroendocrine prostate cancer, Int J Urol, 25, 345, 10.1111/iju.13526 Vlachostergios, 2017, Emerging Variants of Castration-Resistant Prostate Cancer, Curr Oncol Rep, 19, 32, 10.1007/s11912-017-0593-6 Ge, 2020, et al.: epigenetic modulations and lineage plasticity in advanced prostate cancer, Ann Oncol, 31, 470, 10.1016/j.annonc.2020.02.002 Montironi, 2020, Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer, Cells, 9 Tsaur, 2019, Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now, Cancer Treat Rev, 75, 20, 10.1016/j.ctrv.2019.03.001 Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791 Heck, 1988, Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle, Proc Natl Acad Sci U S A, 85, 1086, 10.1073/pnas.85.4.1086 Constantinou, 1989, Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity, Cancer Res, 49, 1110 Tan, 2014, et al.: rb loss is characteristic of prostatic small cell neuroendocrine carcinoma, Clin Cancer Res, 20, 890, 10.1158/1078-0432.CCR-13-1982 Namekawa, 2019, Application of Prostate Cancer Models for Preclinical Study: advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells, Cells, 8 Tai, 2011, PC3 is a cell line characteristic of prostatic small cell carcinoma, Prostate, 71, 1668, 10.1002/pros.21383 Cattrini, 2017, et al.: targeting androgen-independent pathways: new chances for patients with prostate cancer?, Crit Rev Oncol Hematol, 118, 42, 10.1016/j.critrevonc.2017.08.009 Mateo, 2020, et al.: genomics of lethal prostate cancer at diagnosis and castration resistance, J Clin Invest, 130, 1743, 10.1172/JCI132031 Ku, 2017, et al.: rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance, Science, 355, 78, 10.1126/science.aah4199